Aligos Therapeutics

ALGS · Nasdaq · United States

Share price · ALGS

$1.30-5.46 (-80.77%) 3M

close as of 2026-11-18 · 24h delayed · vol 109K (1.8x 30-day avg)

Loading chart…

Prices are end-of-day (EOD), delayed by 24 hours · Adjusted for stock splits · Data via Databento

Compare with peers →

Unusual price moves

Days when ALGS's shares moved far more than they usually do, with what was announced that day or the session before. An announcement on the same day does not show that it caused the move. How the days are picked

  1. 17 Nov 2026-18.1%
  2. 16 Nov 2026-21.0%
  3. 11 Nov 2026-16.0%

    Nothing announced by ALGS that day or the session before.

  4. 10 Nov 2026-34.9%
  5. 6 Nov 2026-9.8%
  6. 31 Aug 2026-15.2%

    Nothing announced by ALGS that day or the session before.

  7. 10 Aug 2026+36.9%

    Nothing announced by ALGS that day or the session before.

  8. 6 Aug 2026+16.2%
  9. 3 Aug 2026+8.7%

    Nothing announced by ALGS that day or the session before.

  10. 24 Jul 2026-13.0%

    Nothing announced by ALGS that day or the session before.

Share of unusual movement by asset

For each asset, the share of ALGS's own-move activity since 3 Sep 2025 that fell on the session of one of the asset's own announcements or the session after it. Large moves count for much more than small ones. A session shared by several assets is split between them. A share is shown once an asset has at least 8 event days; below that, its events are listed instead.

AssetEvent daysShare of unusual movement
Other company news (earnings, financing, releases naming no asset)—9%
Sessions with no dated event—91%

No dated announcements about its assets since 3 Sep 2025.

Assets

(1 total)
1Total Assets
0Approved
0Phase 3 / Filed
1Phase 1–2 / Early
1Diseases
Showing 1 of 1 assets
Target & Modality
Phase 2
Thyroid hormone receptor-betaSmall molecule
MASH / NASH

Upcoming events

No upcoming trial completions or earnings dates on record for this company's assets.

Regulatory and conference events

(1)

Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.

Recent

September 2024Topline resultALG-055009HERALD Phase 2 (NCT06342947) of ALG-055009 in MASH met its primary endpoint
Aligos Therapeutics · Source ↗

Financial reports

Quarterly & interim (16)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2026-Q3$2.8M$19M$32M+ $0 short-term inv.$22M$1.4M operating cash flowreport ↗
View 15 more
PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2026-Q2$0$24M$30M+ $0 short-term inv.$1.5M-$25M operating cash flowreport ↗
2026-Q1$2.8M$23M$30M+ $25M short-term inv.$23M-$23M operating cash flowreport ↗
2025-Q3$0.7M$24M$42M+ $57M short-term inv.$32M-$24M operating cash flowreport ↗
2025-Q2$1.0M$14M$19M+ $104M short-term inv.$16M-$16M operating cash flowreport ↗
2025-Q1$0.3M$15M$74M+ $64M short-term inv.—-$21M operating cash flowreport ↗
2024-Q3$1.3M$17M$35M+ $40M short-term inv.$19M-$20M operating cash flowreport ↗
2024-Q2$1.1M$21M$45M+ $49M short-term inv.—-$19M operating cash flowreport ↗
2024-Q1$0.7M$16M$24M+ $89M short-term inv.$35M-$23M operating cash flowreport ↗
2023-Q3$1.1M$16M$71M$18M-$20M operating cash flowreport ↗
2023-Q2$4.3M$17M$91M+ <$0.1M short-term inv.$19M-$14M operating cash flowreport ↗
2023-Q1$0.1M$18M$79M+ $25M short-term inv.$23M-$22M operating cash flowreport ↗
2022-Q3$0$18M$87M+ $56M short-term inv.$19M-$17M operating cash flowreport ↗
2022-Q2$0$17M$71M+ $88M short-term inv.$20M-$25M operating cash flowreport ↗
2022-Q1—$32M$106M+ $79M short-term inv.$36M-$20M operating cash flowreport ↗
2021-Q3—$28M$240M+ $2.5M short-term inv.$33M-$25M operating cash flowreport ↗

Annual history (5 years)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2025-FY$2.2M$69M$18M+ $60M short-term inv.$6.0M-$83M operating cash flowreport ↗
View 4 more years
PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2024-FY$3.6M$70M$37M+ $20M short-term inv.$33M-$81M operating cash flowreport ↗
2023-FY$6.2M$73M$136M$22M-$79M operating cash flowreport ↗
2022-FY$0$85M$81M+ $44M short-term inv.$24M-$79M operating cash flowreport ↗
2021-FY$0$104M$187M+ $3.9M short-term inv.$32M-$116M operating cash flowreport ↗

Insider transactions

Open-market activity, trailing 12 months: 0 purchases (—), 0 sales (—). Awards, option exercises and tax-withholding rows are listed below but excluded from these totals.

Source
2026-06-25Hirth Peter · directorAward / grant (derivative)5,860——Form 4
2026-06-25Nuechterlein Carole · directorAward / grant (derivative)5,860——Form 4
2026-06-25Scopa James Paul · directorAward / grant (derivative)5,860——Form 4
2026-06-25Martell Bridget A · directorAward / grant (derivative)5,860——Form 4
2026-06-25Chavez Margarita · directorAward / grant (derivative)5,860——Form 4
2026-06-25Preston Heather · directorAward / grant (derivative)5,860——Form 4
2026-03-09BLATT LAWRENCE · director, President and CEOAward / grant (derivative)105,840——Form 4
2026-03-09Calhoun Lesley Ann · See RemarksAward / grant (derivative)37,485——Form 4